Abstract
Purpose
Overexpression of cyclin-dependent kinase (CDK) 4 has been observed in a variety of cancers and has been found to contribute to tumor cell growth and proliferation. However, the effect of inhibition of CDK4 in ovarian cancer is unknown. We investigated the therapeutic effect of the CDK4 inhibitor palbociclib in combination with paclitaxel in ovarian cancer cells.
Methods
Cell viabilities were determined by MTT assay after exposure to different dosages of palbociclib and/or paclitaxel. Western blot, immunofluorescence, and Calcein AM assays were conducted to determine the mechanisms underlying the cytotoxic effects of palbociclib in combination with paclitaxel. CDK4 siRNA was used to validate the outcome of targeting CDK4 by palbociclib in ovarian cancer cells.
Results
We found that combinations of palbociclib and paclitaxel significantly enhanced drug sensitivity in both Rb-positive (SKOV3TR) and Rb-negative (OVCAR8TR) ovarian cancer-derived cells. When combined with paclitaxel, palbociclib induced apoptosis in both SKOV3TR and OVCAR8TR cells. We also found that palbociclib inhibited the activity of P-glycoprotein (Pgp), and that siRNA-mediated CDK4 knockdown sensitized multidrug resistant (MDR) SKOV3TR and OVCAR8TR cells to paclitaxel.
Conclusions
Inhibition of CDK4 by palbociclib can enhance paclitaxel sensitivity in both Rb-positive and Rb-negative MDR ovarian cancer cells by increasing apoptosis. CDK4 may serve as a promising target in the treatment of ovarian cancer.
Similar content being viewed by others
References
R. Siegel, J. Ma, Z. Zou, A. Jemal, Cancer statistics, 2014. CA Cancer J. Clin. 64, 9–29 (2014)
M. Zou, X. Zhang, C. Xu, IL6-induced metastasis modulators p-STAT3, MMP-2 and MMP-9 are targets of 3,3-diindolylmethane in ovarian cancer cells. Cell. Oncol. 39, 47–57 (2016)
M.A. Bookman, M.F. Brady, W.P. McGuire, P.G. Harper, D.S. Alberts, M. Friedlander, N. Colombo, J.M. Fowler, P.A. Argenta, K. De Geest, D.G. Mutch, R.A. Burger, A.M. Swart, E.L. Trimble, C. Accario-Winslow, L.M. Roth, Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the gynecologic cancer intergroup. J. Clin. Oncol. 27, 1419–1425 (2009)
S. Vaughan, J.I. Coward, R.C. Bast Jr., A. Berchuck, J.S. Berek, J.D. Brenton, G. Coukos, C.C. Crum, R. Drapkin, D. Etemadmoghadam, M. Friedlander, H. Gabra, S.B. Kaye, C.J. Lord, E. Lengyel, D.A. Levine, I.A. McNeish, U. Menon, G.B. Mills, K.P. Nephew, A.M. Oza, A.K. Sood, E.A. Stronach, H. Walczak, D.D. Bowtell, F.R. Balkwill, Rethinking ovarian cancer: recommendations for improving outcomes. Nat. Rev. Cancer 11, 719–725 (2011)
B.Y. Karlan, A.M. Oza, G.E. Richardson, D.M. Provencher, V.L. Hansen, M. Buck, S.K. Chambers, P. Ghatage, C.H. Pippitt Jr., J.V. Brown 3rd, A. Covens, R.V. Nagarkar, M. Davy, C.A. Leath 3rd, H. Nguyen, D.E. Stepan, D.M. Weinreich, M. Tassoudji, Y.N. Sun, I.B. Vergote, Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer. J. Clin. Oncol. 30, 362–371 (2012)
M. Strauss, J. Lukas, J. Bartek, Unrestricted cell cycling and cancer. Nat. Med. 1, 1245–1246 (1995)
G. D'Andrilli, C. Kumar, G. Scambia, A. Giordano, Cell cycle genes in ovarian cancer: steps toward earlier diagnosis and novel therapies. Clin. Cancer Res. 10, 8132–8141 (2004)
M. Malumbres, M. Barbacid, Cell cycle, CDKs and cancer: a changing paradigm. Nat. Rev. Cancer 9, 153–166 (2009)
E.A. Musgrove, C.E. Caldon, J. Barraclough, A. Stone, R.L. Sutherland, Cyclin D as a therapeutic target in cancer. Nat. Rev. Cancer 11, 558–572 (2011)
Y. Liao, Y. Feng, J. Shen, F.J. Hornicek and Z. Duan, The roles and therapeutic potential of cyclin-dependent kinases (CDKs) in sarcoma. Cancer Metastasis Rev. 35, 151–163 (2015)
T. Zhang, L.B. Nanney, C. Luongo, L. Lamps, K.J. Heppner, R.N. DuBois, R.D. Beauchamp, Concurrent overexpression of cyclin D1 and cyclin-dependent kinase 4 (Cdk4) in intestinal adenomas from multiple intestinal neoplasia (Min) mice and human familial adenomatous polyposis patients. Cancer Res. 57, 169–175 (1997)
Y. Hashiguchi, H. Tsuda, T. Inoue, S. Nishimura, T. Suzuki, N. Kawamura, Alteration of cell cycle regulators correlates with survival in epithelial ovarian cancer patients. Hum. Pathol. 35, 165–175 (2004)
Y. Yang, B. Ma, L. Li, Y. Jin, W. Ben, D. Zhang, K. Jiang, S. Feng, L. Huang, J. Zheng, CDK2 and CDK4 play important roles in promoting the proliferation of SKOV3 ovarian carcinoma cells induced by tumor-associated macrophages. Oncol. Rep. 31, 2759–2768 (2014)
H. Shinozaki, S. Ozawa, N. Ando, H. Tsuruta, M. Terada, M. Ueda, M. Kitajima, Cyclin D1 amplification as a new predictive classification for squamous cell carcinoma of the esophagus, adding gene information. Clin. Cancer Res. 2, 1155–1161 (1996)
A. DeMichele, A.S. Clark, K.S. Tan, D.F. Heitjan, K. Gramlich, M. Gallagher, P. Lal, M. Feldman, P. Zhang, C. Colameco, D. Lewis, M. Langer, N. Goodman, S. Domchek, K. Gogineni, M. Rosen, K. Fox, P. O'Dwyer, CDK 4/6 inhibitor palbociclib (PD0332991) in Rb + advanced breast cancer: phase II activity, safety, and predictive biomarker assessment. Clin. Cancer Res. 21, 995–1001 (2015)
M.A. Dickson, W.D. Tap, M.L. Keohan, S.P. D'Angelo, M.M. Gounder, C.R. Antonescu, J. Landa, L.X. Qin, D.D. Rathbone, M.M. Condy, Y. Ustoyev, A.M. Crago, S. Singer, G.K. Schwartz, Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma. J. Clin. Oncol. 31, 2024–2028 (2013)
F. Morschhauser, K. Bouabdallah, S. Stilgenbauer, C. Thieblemont, M. Wolf, S. de Guibert, F. Zettl, M. Hahka-Kemppinen, D.X. Wang, P. Brueck, Clinical activity of abemaciclib (LY2835219), a cell cycle inhibitor selective for CDK4 and CDK6, in patients with relapsed or refractory mantle cell lymphoma. Blood 124, 3067–3067 (2014)
J.R. Infante, G. Shapiro, P. Witteveen, J.F. Gerecitano, V. Ribrag, R. Chugh, I. Issa, A. Chakraborty, A. Matano and X. Zhao, In ASCO Annual Meeting Proceedings, p. 2528 (2014)
R.S. Finn, J.P. Crown, I. Lang, K. Boer, I.M. Bondarenko, S.O. Kulyk, J. Ettl, R. Patel, T. Pinter, M. Schmidt, Y. Shparyk, A.R. Thummala, N.L. Voytko, C. Fowst, X. Huang, S.T. Kim, S. Randolph, D.J. Slamon, The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 16, 25–35 (2015)
D.W. Fry, P.J. Harvey, P.R. Keller, W.L. Elliott, M. Meade, E. Trachet, M. Albassam, X. Zheng, W.R. Leopold, N.K. Pryer, P.L. Toogood, Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol. Cancer Ther. 3, 1427–1438 (2004)
J. Halder, C.N. Landen Jr., S.K. Lutgendorf, Y. Li, N.B. Jennings, D. Fan, G.M. Nelkin, R. Schmandt, M.D. Schaller, A.K. Sood, Focal adhesion kinase silencing augments docetaxel-mediated apoptosis in ovarian cancer cells. Clin. Cancer Res. 11, 8829–8836 (2005)
X. Yang, J. Shen, Y. Gao, Y. Feng, Y. Guan, Z. Zhang, H. Mankin, F.J. Hornicek, Z. Duan, Nsc23925 prevents the development of paclitaxel resistance by inhibiting the introduction of P-glycoprotein and enhancing apoptosis. Int. J. Cancer 137, 2029–2039 (2015)
X. Yang, A.K. Iyer, A. Singh, L. Milane, E. Choy, F.J. Hornicek, M.M. Amiji, Z. Duan, Cluster of differentiation 44 targeted hyaluronic acid based nanoparticles for MDR1 siRNA delivery to overcome drug resistance in ovarian cancer. Pharm. Res. 32, 2097–2109 (2015)
H. Devalapally, Z. Duan, M.V. Seiden, M.M. Amiji, Modulation of drug resistance in ovarian adenocarcinoma by enhancing intracellular ceramide using tamoxifen-loaded biodegradable polymeric nanoparticles. Clin. Cancer Res. 14, 3193–3203 (2008)
Z. Duan, K.A. Brakora, M.V. Seiden, Inhibition of ABCB1 (MDR1) and ABCB4 (MDR3) expression by small interfering RNA and reversal of paclitaxel resistance in human ovarian cancer cells. Mol. Cancer Ther. 3, 833–838 (2004)
Z. Duan, A.J. Feller, R.T. Penson, B.A. Chabner, M.V. Seiden, Discovery of differentially expressed genes associated with paclitaxel resistance using cDNA array technology: analysis of interleukin (IL) 6, IL-8, and monocyte chemotactic protein 1 in the paclitaxel-resistant phenotype. Clin. Cancer Res. 5, 3445–3453 (1999)
W.R. Sellers, W.G. Kaelin Jr., Role of the retinoblastoma protein in the pathogenesis of human cancer. J. Clin. Oncol. 15, 3301–3312 (1997)
T.U. Barbie, D.A. Barbie, D.T. MacLaughlin, S. Maheswaran, P.K. Donahoe, Mullerian inhibiting substance inhibits cervical cancer cell growth via a pathway involving p130 and p107. Proc. Natl. Acad. Sci. U. S. A. 100, 15601–15606 (2003)
T.U. Ha, D.L. Segev, D. Barbie, P.T. Masiakos, T.T. Tran, D. Dombkowski, M. Glander, T.R. Clarke, H.K. Lorenzo, P.K. Donahoe, S. Maheswaran, Mullerian inhibiting substance inhibits ovarian cell growth through an Rb-independent mechanism. J. Biol. Chem. 275, 37101–37109 (2000)
K. Milde-Langosch, M. Hagen, A.M. Bamberger, T. Loning, Expression and prognostic value of the cell-cycle regulatory proteins, Rb, p16MTS1, p21WAF1, p27KIP1, cyclin E, and cyclin D2, in ovarian cancer. Int. J. Gynecol. Pathol. 22, 168–174 (2003)
J.P. Leonard, A.S. LaCasce, M.R. Smith, A. Noy, L.R. Chirieac, S.J. Rodig, J.Q. Yu, S. Vallabhajosula, H. Schoder, P. English, D.S. Neuberg, P. Martin, M.M. Millenson, S.A. Ely, R. Courtney, N. Shaik, K.D. Wilner, S. Randolph, A.D. Van den Abbeele, S.Y. Chen-Kiang, J.T. Yap, G.I. Shapiro, Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. Blood 119, 4597–4607 (2012)
C.K. Ingemarsdotter, L.A. Tookman, A. Browne, K. Pirlo, R. Cutts, C. Chelela, K.F. Khurrum, E.Y. Leung, S. Dowson, L. Webber, I. Khan, D. Ennis, N. Syed, T.R. Crook, J.D. Brenton, M. Lockley, I.A. McNeish, Paclitaxel resistance increases oncolytic adenovirus efficacy via upregulated CAR expression and dysfunctional cell cycle control. Mol. Oncol. 9, 791–805 (2015)
A.S. Clark, P.J. O'Dwyer, D. Heitjan, P. Lal, M.D. Feldman, M. Gallagher, C. Redlinger, C. Colameco, D. Lewis, K. Zafman, M. Langer, M.A. Rosen, K. Gogineni, A.R. Bradbury, S.M. Domchek, K.R. Fox, A. DeMichele, A phase I trial of palbociclib and paclitaxel in metastatic breast cancer. J. Clin. Oncol. 32, 5 (2014)
S. Patel, L. Kumar, N. Singh, Metformin and epithelial ovarian cancer therapeutics. Cell. Oncol. 38, 365–375 (2015)
K. Goetze, C.G. Fabian, A. Siebers, L. Binz, D. Faber, S. Indraccolo, G. Nardo, U.G. Sattler, W. Mueller-Klieser, Manipulation of tumor metabolism for therapeutic approaches: ovarian cancer-derived cell lines as a model system. Cell. Oncol. 38, 377–385 (2015)
R.I. Sanchez, S. Mesia-Vela, F.C. Kauffman, Challenges of cancer drug design: a drug metabolism perspective. Curr. Cancer Drug Targets 1, 1–32 (2001)
A.M. Reed, M.L. Fishel, M.R. Kelley, Small-molecule inhibitors of proteins involved in base excision repair potentiate the anti-tumorigenic effect of existing chemotherapeutics and irradiation. Future Oncol. 5, 713–726 (2009)
D.C. Altieri, The case for survivin as a regulator of microtubule dynamics and cell-death decisions. Curr. Opin. Cell Biol. 18, 609–615 (2006)
N. Bah, L. Maillet, J. Ryan, S. Dubreil, F. Gautier, A. Letai, P. Juin, S. Barille-Nion, Bcl-xL controls a switch between cell death modes during mitotic arrest. Cell Death Dis. 5, e1291 (2014)
S.N. Kolomeichuk, D.T. Terrano, C.S. Lyle, K. Sabapathy, T.C. Chambers, Distinct signaling pathways of microtubule inhibitors--vinblastine and Taxol induce JNK-dependent cell death but through AP-1-dependent and AP-1-independent mechanisms, respectively. FEBS J. 275, 1889–1899 (2008)
S.J. Lim, M.K. Choi, M.J. Kim, J.K. Kim, Alpha-tocopheryl succinate potentiates the paclitaxel-induced apoptosis through enforced caspase 8 activation in human H460 lung cancer cells. Exp. Mol. Med. 41, 737–745 (2009)
X.H. Zhang, Y. Cheng, J.Y. Shin, J.O. Kim, J.E. Oh, J.H. Kang, A CDK4/6 inhibitor enhances cytotoxicity of paclitaxel in lung adenocarcinoma cells harboring mutant KRAS as well as wild-type KRAS. Cancer Biol. Ther. 14, 597–605 (2013)
D.W. Fry, D.C. Bedford, P.H. Harvey, A. Fritsch, P.R. Keller, Z. Wu, E. Dobrusin, W.R. Leopold, A. Fattaey, M.D. Garrett, Cell cycle and biochemical effects of PD 0183812. A potent inhibitor of the cyclin D-dependent kinases CDK4 and CDK6. J. Biol. Chem. 276, 16617–16623 (2001)
B. Taylor-Harding, P.J. Aspuria, H. Agadjanian, D.J. Cheon, T. Mizuno, D. Greenberg, J.R. Allen, L. Spurka, V. Funari, E. Spiteri, Q. Wang, S. Orsulic, C. Walsh, B.Y. Karlan, W.R. Wiedemeyer, Cyclin E1 and RTK/RAS signaling drive CDK inhibitor resistance via activation of E2F and ETS. Oncotarget 6, 696–714 (2015)
G.E. Konecny, B. Winterhoff, T. Kolarova, J. Qi, K. Manivong, J. Dering, G. Yang, M. Chalukya, H.J. Wang, L. Anderson, K.R. Kalli, R.S. Finn, C. Ginther, S. Jones, V.E. Velculescu, D. Riehle, W.A. Cliby, S. Randolph, M. Koehler, L.C. Hartmann, D.J. Slamon, Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer. Clin. Cancer Res. 17, 1591–1602 (2011)
G. Szakacs, J.K. Paterson, J.A. Ludwig, C. Booth-Genthe, M.M. Gottesman, Targeting multidrug resistance in cancer. Nat. Rev. Drug Discov. 5, 219–234 (2006)
Z. Wang, Y. Chen, H. Liang, A. Bender, R.C. Glen, A. Yan, P-glycoprotein substrate models using support vector machines based on a comprehensive data set. J. Chem. Inf. Model. 51, 1447–1456 (2011)
T. Hegedus, L. Orfi, A. Seprodi, A. Varadi, B. Sarkadi, G. Keri, Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1. Biochim. Biophys. Acta 1587, 318–325 (2002)
X.K. Wang, L.W. Fu, Interaction of tyrosine kinase inhibitors with the MDR-related ABC transporter proteins. Curr. Drug Metab. 11, 618–628 (2010)
Z. Duan, A.J. Feller, H.C. Toh, T. Makastorsis, M.V. Seiden, TRAG-3, a novel gene, isolated from a taxol-resistant ovarian carcinoma cell line. Gene 229, 75–81 (1999)
Acknowledgements
This work was supported in part by grants from the Gattegno and Wechsler funds. Dr. Duan is supported, in part, through a grant from the Sarcoma Foundation of America (SFA), a pilot grant from Sarcoma SPORE/NIH, and a grant from the National Cancer Institute (NCI)/National Institutes of Health (NIH), UO1, CA 151452.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no competing interests.
Rights and permissions
About this article
Cite this article
Gao, Y., Shen, J., Choy, E. et al. Inhibition of CDK4 sensitizes multidrug resistant ovarian cancer cells to paclitaxel by increasing apoptosiss. Cell Oncol. 40, 209–218 (2017). https://doi.org/10.1007/s13402-017-0316-x
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13402-017-0316-x